NCT07507799

Brief Summary

The original EXORA block used high local anesthetic volume (50 mL total), raising concerns about local anesthetic systemic toxicity (LAST). In such a bilaterally administered regional technique, evaluating the efficacy of a reduced-volume approach is warranted to maximize patient safety.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for not_applicable

Timeline
5mo left

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress32%
Apr 2026Nov 2026

First Submitted

Initial submission to the registry

March 25, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 2, 2026

Completed
8 days until next milestone

Study Start

First participant enrolled

April 10, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2026

Last Updated

April 16, 2026

Status Verified

April 1, 2026

Enrollment Period

7 months

First QC Date

March 25, 2026

Last Update Submit

April 13, 2026

Conditions

Keywords

EXORAanalgesic efficacylow volumelaparoscopic cholecystectomy

Outcome Measures

Primary Outcomes (1)

  • Dynamic numerical rating scale (NRS) score at 4 hours postoperatively.

    From 0 to 10 where 0 denote no pain and 10 denote the worst pain ever experienced with cough

    4 hours after surgery

Secondary Outcomes (13)

  • Static Numerical Rating scale NRS scores

    up to 24 hours post operatively

  • Dynamic numerical rating scale NRS scores

    up to 24 hours post operatively

  • Cumulative Static Pain Burden

    Up to 24h postoperatively

  • Cumulative Dynamic Pain Burden

    Up to 24h postoperatively

  • Intraoperative Fentanyl consumption Total fentanyl in micrograms

    From induction of anesthesia until patient is transferred to postoperative care unit up to 4 hours]

  • +8 more secondary outcomes

Study Arms (2)

EXORA 15

ACTIVE COMPARATOR

15 mL of bupivacaine 0.25% administered bilaterally

Procedure: EXORA block 15

EXORA 25

ACTIVE COMPARATOR

25 mL of bupivacaine 0.25% administered bilaterally

Procedure: EXORA block 25

Interventions

15 mL of bupivacaine 0.25% administered bilaterally by ultrasound guided EXORA block

EXORA 15

25 mL of bupivacaine 0.25% administered bilaterally by ultrasound guided EXORA block

EXORA 25

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia.

You may not qualify if:

  • Patient refusal to participate.
  • Obese patients with a body mass index of more than 35 kg/m2.
  • Known cognitive impairment or use of psychiatric drugs
  • Known allergy to local anesthetics
  • Infection at the needle insertion site.
  • Coagulopathy, or bleeding disorders.
  • Pregnancy
  • History of chronic pain or chronic opioid use.
  • Previous major upper abdominal surgery (which alters the fascial planes and anatomy).
  • Criteria for Withdrawal from Study Analysis (Drop-outs):
  • Conversion to open cholecystectomy during surgery.
  • Failed EXORA block

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fayoum University hospital

El Fayoum Qesm, Faiyum Governorate, 63514, Egypt

Location

Related Publications (6)

  • Okmen K, Demirel A, Dogan AK, Ertus CY. Application of EXORA block for analgesia following hand-assisted laparoscopic donor nephrectomy (HALDN). Indian J Anaesth. 2025 Mar;69(3):324-326. doi: 10.4103/ija.ija_1263_24. Epub 2025 Feb 17. No abstract available.

    PMID: 40161911BACKGROUND
  • Okmen K, Yildiz DK, Ulker GK. Evaluation of the efficacy of M-TAPA and EXORA block application for analgesia after laparoscopic cholecystectomy: a prospective, single-blind, observational study. Korean J Anesthesiol. 2025 Aug;78(4):361-368. doi: 10.4097/kja.24563. Epub 2025 Apr 15.

    PMID: 40230270BACKGROUND
  • Fernandez Martin MT, Lopez Alvarez S, Valdes-Vilches LF. EXORA block: a new approach for laparoscopic cholecystectomy analgesia? Minerva Anestesiol. 2024 May;90(5):462-463. doi: 10.23736/S0375-9393.23.17863-1. Epub 2024 Jan 29. No abstract available.

    PMID: 38287777BACKGROUND
  • Kumar K, Kirksey MA, Duong S, Wu CL. A Review of Opioid-Sparing Modalities in Perioperative Pain Management: Methods to Decrease Opioid Use Postoperatively. Anesth Analg. 2017 Nov;125(5):1749-1760. doi: 10.1213/ANE.0000000000002497.

    PMID: 29049119BACKGROUND
  • De Cassai A, Sella N, Geraldini F, Tulgar S, Ahiskalioglu A, Dost B, Manfrin S, Karapinar YE, Paganini G, Beldagli M, Luoni V, Ordulu BBK, Boscolo A, Navalesi P. Single-shot regional anesthesia for laparoscopic cholecystectomies: a systematic review and network meta-analysis. Korean J Anesthesiol. 2023 Feb;76(1):34-46. doi: 10.4097/kja.22366. Epub 2022 Nov 8.

    PMID: 36345156BACKGROUND
  • Ekstein P, Szold A, Sagie B, Werbin N, Klausner JM, Weinbroum AA. Laparoscopic surgery may be associated with severe pain and high analgesia requirements in the immediate postoperative period. Ann Surg. 2006 Jan;243(1):41-6. doi: 10.1097/01.sla.0000193806.81428.6f.

    PMID: 16371735BACKGROUND

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Mohamed A Hamed,, MD

    Faculty of medicine, Fayoum university

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mohammed R Gomaa, Bch

CONTACT

Mohamed H Ragab, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Anesthesiology

Study Record Dates

First Submitted

March 25, 2026

First Posted

April 2, 2026

Study Start

April 10, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 2, 2026

Last Updated

April 16, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations